La vendita allo scoperto per Rigel Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Rigel Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Rigel Pharmaceuticals (NASDAQ:RIGL) Azioni, Report sulle vendite allo scoperto

Rigel Pharmaceuticals

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals Inc

News

RIGL

Optime Care Expands Partnership With Rigel Pharmaceuticals To Include Commercial Distribution Of TAVALISSE For Managing Chronic Immune Thrombocytopenia

Cantor Fitzgerald analyst Kristen Kluska reiterates Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Neutral and maintains $15 price target.

Price Target

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Neutral on Rigel Pharmaceuticals, Maintains $15 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Buy and maintains $57 price target.

HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target

Rigel Says First Patient Enrolled In Phase 1b/2 Triplet Therapy Trial Of Decitabine And Venetoclax In Combination With REZLIDHIA

<ul>
<li>Kissei gains exclusive rights to develop and commercialize olutasidenib in all current and potential indications in Japan, the Republic of Korea&nbsp;and Taiwan</li>
<li>Rigel will receive&nbsp;an upfront cash payment of $10.0 million with the potential for up to $152.5 million in future development, regulatory, and commercial milestone payments</li>
<li>Rigel to receive product transfer price payments in the mid-twenty to lower-thirty percent range based on tiered net sales for exclusive supply of REZLIDHIA</li>
</ul>
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced it has entered into an exclusive license and supply agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") to develop and commercialize REZLIDHIA&#xAE; (olutasidenib)&nbsp;in all current and potential indications in Japan, the Republic of Korea (Korea) and Taiwan. REZLIDHIA is commercially available to patients in the U.S. for the treatment of relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML). Rigel has an existing agreement with Kissei to develop and commercialize TAVALISSE&#xAE; (fostamatinib disodium hexahydrate) for the treatment of chronic immune thrombocytopenia (ITP) and in all other potential indications in Japan, China, Taiwan and the Republic of Korea.

Biotech

Global

General

Rigel Expands Relationship With Kissei To include REZLIDHIA In Japan, The Republic Of Korea And Taiwan; Will Receive An Upfront Cash Payment Of $10M With The Potential For Up To $152.5M In Future Development, Regulatory, And Commercial Milestone Payments

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Buy with 1-for-10 Reverse Stock Split.

CORRECTION: HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals (1-for-10 Reverse Stock Split) - Headline Earlier Published on 9th Aug

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Buy, adjusts target to $57 from $15 (1-20 Reverse Stock Split).

HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Adjusts Price Target To $57 (1-20 Reverse Stock Split)

Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.

Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.31) by 80.65 percent. The company reported quarterly sales of $36.841 million which beat the analyst consensus estimate of $33.419 million by 10.24 percent. This is a 37.03 percent increase over sales of $26.886 million the same period last year.

Earnings

Earnings Beats

Rigel Pharmaceuticals Q2 2024 GAAP EPS $(0.06) Beats $(0.31) Estimate, Sales $36.841M Beat $33.419M Estimate

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Rigel Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) today announced that it will effect a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10 (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern Time on Thursday, June 27, 2024. The company's common stock will begin trading on a post-split basis on The Nasdaq Global Select Market under the same symbol (RIGL) when the market opens on Thursday, June 27, 2024, with the new CUSIP number 766559702.
The Reverse Stock Split was approved by the company's stockholders at its Annual Meeting of Stockholders held on May 24, 2024 to be effected by the company's Board of Directors (the "Board") within approved parameters. The final ratio was approved by the Board on June 15, 2024. As a result of the Reverse Stock Split, every 10 shares of the company's pre-split common stock issued and outstanding will be automatically reclassified into one new share of the company's common stock. This will reduce the number of shares outstanding from approximately 175,582,945 shares to approximately 17,558,294, subject to adjustment due to the payment of cash in lieu of fractional shares. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the company's equity plans, as applicable. The Reverse Stock Split will not affect the number of authorized shares of common stock or the par value of the common stock.

Stock Split

Rigel Announces 1-For-10 Reverse Stock Split, Will Begin Trading On A Post-Split Basis When The Market Opens On Thursday, June 27, 2024

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Buy and maintains $15 price target.

HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $15 Price Target

GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024
SOUTH SAN FRANCISCO, Calif., June 24, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) today announced the completion of the transfer to Rigel of the New Drug Application (NDA) for GAVRETO&#xAE; (pralsetinib) for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by a U.S. Food and Drug Administration (FDA) approved test and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). GAVRETO will be commercially available from Rigel in the U.S. by prescription beginning June 27, 2024.

Rigel Pharmaceuticals Completes Transfer Of GAVRETO New Drug Application; Will Be Available In The U.S. Beginning June 27, 2024

<div>Oral presentation of final five-year results from the registrational Phase 2 trial in R/R mIDH1 AML patients reinforces REZLIDHIA&nbsp;(olutasidenib) efficacy in heavily pretreated patients, including those receiving prior venetoclax.</div>

Rigel Plans Presentations At The Upcoming 2024 ASCO Annual Meeting And EHA2024 Hybrid Congress

WIIM

Rigel Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 financial results.

Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.03) by 66.67 percent. This is a 37.5 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $29.534 million which missed the analyst consensus estimate of $31.284 million by 5.59 percent. This is a 13.29 percent increase over sales of $26.070 million the same period last year.

Earnings Misses

Rigel Pharmaceuticals Q1 2024 GAAP EPS $(0.05) Misses $(0.03) Estimate, Sales $29.534M Miss $31.284M Estimate

Rigel announces reverse stock split

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Rigel Pharmaceuticals GAAP EPS of -$0.06 beats by $0.14, revenue of $36.84M beats by $3.14M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Rigel Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/rigl-stock-quote/">RIGL</a>) just reported results for the second quarter of 2024.<ul><li>Rigel Pharmaceuticals reported earnings per share of -6 cents. This was above the analyst estimate for EPS of -29 cents.</li><li>The company reported revenue of $36.84 million.</li><li>This was 10.24% better than the analyst estimate for revenue of $33.42 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/rigl-stock-earnings-rigel-pharmaceuticals-for-q2-of-2024/">RIGL Stock Earnings: Rigel Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RIGL Stock Earnings: Rigel Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rigel (RIGL – Research Report) and IDEAYA Bioscience...

Analysts Offer Insights on Healthcare Companies: Rigel (RIGL) and IDEAYA Biosciences (IDYA)

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2024 Earnings Call Transcript

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rigel (RIGL – Research Report) and keeping the price target at $57.00. Jos...

Buy Rating Affirmed for Rigel with Positive Outlook on Asian Market Expansion and Solid NPV Valuation

An announcement from Rigel ( ($RIGL) ) is now available. Dr. Brian Kotzin has decided to step down from his role as an independent director on Rige...

Comments

Rigel Pharmaceuticals

Vendite allo scoperto

Rigel Pharmaceuticals (NASDAQ:RIGL) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO